---
title: "LRMR: Nomlabofusp shows sustained efficacy and safety in FA, with BLA submission and phase III underway"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291161119.md"
description: "Nomlabofusp demonstrated sustained increases in frataxin and improvements in key clinical outcomes for Friedreich's ataxia, with a favorable safety profile and strong patient interest. Rolling BLA submission is underway, and a global phase III trial will begin soon, targeting a broad patient population.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-06-29T14:24:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291161119.md)
  - [en](https://longbridge.com/en/news/291161119.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291161119.md)
---

# LRMR: Nomlabofusp shows sustained efficacy and safety in FA, with BLA submission and phase III underway

Nomlabofusp demonstrated sustained increases in frataxin and improvements in key clinical outcomes for Friedreich's ataxia, with a favorable safety profile and strong patient interest. Rolling BLA submission is underway, and a global phase III trial will begin soon, targeting a broad patient population.

Based on

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [LRMR.US](https://longbridge.com/en/quote/LRMR.US.md)

## Related News & Research

- [Regulatory and Manufacturing Risks Cloud Larimar Therapeutics’ Accelerated Approval Path for Nomlabofusp](https://longbridge.com/en/news/294920945.md)
- [Larimar Therapeutics Q2 net loss widens to $32.78 million; R&D expenses rise to $28 million](https://longbridge.com/en/news/294812276.md)
- [KYP: Profit and SaaS revenue surged as AI transformation and regulatory demand fueled growth](https://longbridge.com/en/news/295034006.md)
- [Larimar Therapeutics (LRMR) to Announce Earnings on Thursday](https://longbridge.com/en/news/295068495.md)
- [Relmada publishes investor presentation highlighting NDV-01 program for non-muscle invasive bladder cancer](https://longbridge.com/en/news/295148682.md)